{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T23:15:46Z","timestamp":1769210146100,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pfizer Pharma GmbH","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00702-019-02122-9","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T12:02:56Z","timestamp":1576843376000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Olfactory dysfunction correlates with putaminal dopamine turnover in early de novo Parkinson\u2019s disease"],"prefix":"10.1007","volume":"127","author":[{"given":"Matthias","family":"L\u00f6hle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Beuthien-Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liane","family":"Oehme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"van den Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Kotzerke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Reichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1133-9216","authenticated-orcid":false,"given":"Alexander","family":"Storch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"issue":"1\u20132","key":"2122_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2011.06.020","volume":"310","author":"HW Berendse","year":"2011","unstructured":"Berendse HW, Roos DS, Raijmakers P, Doty RL (2011) Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease. J Neurol Sci 310(1\u20132):21\u201324","journal-title":"J Neurol Sci"},{"issue":"1","key":"2122_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s00415-006-0284-y","volume":"254","author":"NI Bohnen","year":"2007","unstructured":"Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY (2007) Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 254(1):84\u201390","journal-title":"J Neurol"},{"issue":"Pt 6","key":"2122_CR3","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/brain\/awq079","volume":"133","author":"NI Bohnen","year":"2010","unstructured":"Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, Frey KA (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 133(Pt 6):1747\u20131754","journal-title":"Brain"},{"issue":"12","key":"2122_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/qjmed\/hcq142","volume":"103","author":"J Deeb","year":"2010","unstructured":"Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ, Hawkes CH (2010) A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease. QJM 103(12):941\u2013952","journal-title":"QJM"},{"issue":"8","key":"2122_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1212\/WNL.38.8.1237","volume":"38","author":"RL Doty","year":"1988","unstructured":"Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38(8):1237\u20131244","journal-title":"Neurology"},{"key":"2122_CR6","unstructured":"Fahn S, Elton RL, Committee UD (1987) The Unified Parkinson\u2019s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB (eds) Recent developments in Parkinson\u2019s disease., vol 2. Macmillan Healthcare Information, Florham Park, pp 153\u2013163, 293\u2013304"},{"issue":"9","key":"2122_CR7","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00415-015-7830-4","volume":"262","author":"C Georgiopoulos","year":"2015","unstructured":"Georgiopoulos C, Davidsson A, Engstrom M, Larsson EM, Zachrisson H, Dizdar N (2015) The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes. J Neurol 262(9):2154\u20132163","journal-title":"J Neurol"},{"issue":"8","key":"2122_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.parkreldis.2008.01.010","volume":"14","author":"DS Goldstein","year":"2008","unstructured":"Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, Imrich R, Conant S, Eldadah BA (2008) Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 14(8):600\u2013607","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2122_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1212\/WNL.0b013e3181ca014c","volume":"74","author":"DS Goldstein","year":"2010","unstructured":"Goldstein DS, Sewell L, Holmes C (2010) Association of anosmia with autonomic failure in Parkinson disease. Neurology 74(3):245\u2013251","journal-title":"Neurology"},{"issue":"7","key":"2122_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.parkreldis.2008.12.005","volume":"15","author":"A Haehner","year":"2009","unstructured":"Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, Johnston AN, Mellick GD, Herting B, Reichmann H, Hummel T (2009) Prevalence of smell loss in Parkinson's disease\u2013a multicenter study. Parkinsonism Relat Disord 15(7):490\u2013494","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"2122_CR11","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1007\/s00415-013-7153-2","volume":"260","author":"A Hahner","year":"2013","unstructured":"Hahner A, Maboshe W, Baptista RB, Storch A, Reichmann H, Hummel T (2013) Selective hyposmia in Parkinson's disease? J Neurol 260(12):3158\u20133160","journal-title":"J Neurol"},{"issue":"5","key":"2122_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp.62.5.436","volume":"62","author":"CH Hawkes","year":"1997","unstructured":"Hawkes CH, Shephard BC, Daniel SE (1997) Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 62(5):436\u2013446","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2122_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00415-008-0665-5","volume":"255","author":"B Herting","year":"2008","unstructured":"Herting B, Schulze S, Reichmann H, Haehner A, Hummel T (2008) A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease. J Neurol 255(3):367\u2013370","journal-title":"J Neurol"},{"issue":"5","key":"2122_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427\u2013442","journal-title":"Neurology"},{"issue":"3","key":"2122_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2122_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/chemse\/22.1.39","volume":"22","author":"T Hummel","year":"1997","unstructured":"Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G (1997) 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22(1):39\u201352","journal-title":"Chem Senses"},{"issue":"3","key":"2122_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00405-006-0173-0","volume":"264","author":"T Hummel","year":"2007","unstructured":"Hummel T, Kobal G, Gudziol H, Mackay-Sim A (2007) Normative data for the \"Sniffin' Sticks\" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264(3):237\u2013243","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"2122_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-018-0450-0","volume":"8","author":"S Jakobson Mo","year":"2018","unstructured":"Jakobson Mo S, Axelsson J, Jonasson L, Larsson A, Ogren MJ, Ogren M, Varrone A, Eriksson L, Backstrom D, Af Bjerken S, Linder J, Riklund K (2018) Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT-a clinical comparison. EJNMMI Res 8(1):100","journal-title":"EJNMMI Res"},{"issue":"19","key":"2122_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1212\/WNL.0000000000000960","volume":"83","author":"D Jennings","year":"2014","unstructured":"Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K, Investigators P (2014) Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 83(19):1739\u20131746","journal-title":"Neurology"},{"issue":"4","key":"2122_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","volume":"47","author":"CS Lee","year":"2000","unstructured":"Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47(4):493\u2013503","journal-title":"Ann Neurol"},{"issue":"3","key":"2122_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1212\/WNL.0000000000002286","volume":"86","author":"M Lohle","year":"2016","unstructured":"Lohle M, Mende J, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, Kotzerke J, Reichmann H, Storch A (2016) Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications. Neurology 86(3):231\u2013240","journal-title":"Neurology"},{"issue":"9","key":"2122_CR22","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/mds.27466","volume":"33","author":"M Lohle","year":"2018","unstructured":"Lohle M, Mangone G, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, Kotzerke J, Reichmann H, Corvol JC, Storch A (2018) Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease. Mov Disord 33(9):1496\u20131501","journal-title":"Mov Disord"},{"key":"2122_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3233\/JPD-191672","volume":"9","author":"M Lohle","year":"2019","unstructured":"Lohle M, Hermann W, Hausbrand D, Wolz M, Mende J, Beuthien-Baumann B, Oehme L, van den Hoff J, Kotzerke J, Reichmann H, Hermann A, Storch A (2019) Putaminal dopamine turnover in de novo Parkinson's disease predicts later neuropsychiatric fluctuations but not other major health outcomes. J Parkinson's Dis 9:693\u2013704","journal-title":"J Parkinson's Dis"},{"issue":"3","key":"2122_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/mds.27282","volume":"33","author":"AJ Noyce","year":"2018","unstructured":"Noyce AJ, Dickson J, Rees RN, Bestwick JP, Isaias IU, Politis M, Giovannoni G, Warner TT, Lees AJ, Schrag A (2018) Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Mov Disord 33(3):478\u2013482","journal-title":"Mov Disord"},{"issue":"8","key":"2122_CR25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s00259-011-1819-8","volume":"38","author":"L Oehme","year":"2011","unstructured":"Oehme L, Perick M, Beuthien-Baumann B, Wolz M, Storch A, Lohle M, Herting B, Langner J, van den Hoff J, Reichmann H, Kotzerke J (2011) Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with (1)(8)F-dopa brain PET in normal controls and patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 38(8):1550\u20131559","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2122_CR26","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1007\/s00330-017-5147-7","volume":"28","author":"K Pak","year":"2018","unstructured":"Pak K, Kim K, Lee MJ, Lee JM, Kim BS, Kim SJ, Kim IJ (2018) Correlation between the availability of dopamine transporter and olfactory function in healthy subjects. Eur Radiol 28(4):1756\u20131760","journal-title":"Eur Radiol"},{"issue":"5","key":"2122_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.neuint.2006.03.013","volume":"49","author":"C Pifl","year":"2006","unstructured":"Pifl C, Hornykiewicz O (2006) Dopamine turnover is upregulated in the caudate\/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int 49(5):519\u2013524","journal-title":"Neurochem Int"},{"issue":"2","key":"2122_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ana.21291","volume":"63","author":"GW Ross","year":"2008","unstructured":"Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR (2008) Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 63(2):167\u2013173","journal-title":"Ann Neurol"},{"issue":"10","key":"2122_CR29","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/01.WNL.0000161874.52302.5D","volume":"64","author":"A Siderowf","year":"2005","unstructured":"Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, Stern MB, Doty RL, Mozley PD, Wintering N, Duda JE, Weintraub D, Moberg PJ (2005) [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64(10):1716\u20131720","journal-title":"Neurology"},{"issue":"4","key":"2122_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00004647-200104000-00015","volume":"21","author":"V Sossi","year":"2001","unstructured":"Sossi V, Doudet DJ, Holden JE (2001) A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 21(4):469\u2013476","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"2122_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/01.WCB.0000050041.22945.3E","volume":"23","author":"V Sossi","year":"2003","unstructured":"Sossi V, Holden JE, de la Fuente-Fernandez R, Ruth TJ, Stoessl AJ (2003) Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant K\nocc and the [18F]fluorodopa plasma input uptake rate constant Ki. J Cereb Blood Flow Metab 23(3):301\u2013309","journal-title":"J Cereb Blood Flow Metab"},{"issue":"Pt 4","key":"2122_CR32","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/brain\/awl028","volume":"129","author":"V Sossi","year":"2006","unstructured":"Sossi V, de la Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J (2006) Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 129(Pt 4):1050\u20131058","journal-title":"Brain"},{"issue":"5","key":"2122_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/ana.21204","volume":"62","author":"V Sossi","year":"2007","unstructured":"Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ (2007) Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 62(5):468\u2013474","journal-title":"Ann Neurol"},{"issue":"16","key":"2122_CR34","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/mds.23356","volume":"25","author":"V Sossi","year":"2010","unstructured":"Sossi V, de la Fuente-Fernandez R, Nandhagopal R, Schulzer M, McKenzie J, Ruth TJ, Aasly JO, Farrer MJ, Wszolek ZK, Stoessl JA (2010) Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 25(16):2717\u20132723","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"2122_CR35","doi-asserted-by":"publisher","first-page":"S421","DOI":"10.1016\/S1353-8020(08)70041-5","volume":"13","author":"AJ Stoessl","year":"2007","unstructured":"Stoessl AJ (2007) Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat Disord 13(Suppl 3):S421\u2013424","journal-title":"Parkinsonism Relat Disord"},{"issue":"19","key":"2122_CR36","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1212\/WNL.0b013e3182918c2d","volume":"80","author":"A Storch","year":"2013","unstructured":"Storch A, Wolz M, Beuthien-Baumann B, Lohle M, Herting B, Schwanebeck U, Oehme L, van den Hoff J, Perick M, Grahlert X, Kotzerke J, Reichmann H (2013) Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology 80(19):1754\u20131761","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02122-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02122-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02122-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T00:29:34Z","timestamp":1608337774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02122-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2122"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02122-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. L\u00f6hle has received has received honoraria for presentations from Bayer Healthcare and UCB Pharma. Dr. Wolz reports personal fees from Boehringer Ingelheim, Zambon, Valeant, Desitin, TEVA, UCB Pharma, Abbvie, Licher, and Daiichi Sankyo, outside the submitted work. B. Beuthien-Baumann has received honoraria for presentations\/lectures from BRACCO and Roche Pharma AG, Basel, Switzerland. Dr. Oehme reports no disclosures. Dr. van den Hoff reports no disclosures. Dr. Kotzerke reports no disclosures. H. Reichmann was acting on advisory boards and gave lectures and received research grants from Bayer Health Care, Boehringer\/Ingelheim, Cephalon, Desitin, GlaxoSmithKline, Merck-Serono, Novartis, Orion, Pfizer, Solvay, TEVA\/Lundbeck, UCB Pharma, and Valeant. Dr. Storch has received funding from the Deutsche Forschungsgemeinschaft (DFG) and the Helmholtz Association. He received unrestricted research grants from GKC Melbourne, Pfizer, and TEVA Pharma, honoraria for presentations\/lectures\/consultancies or advisory boards from AbbVie, Bayer Healthcare, Bial, GKC, Gr\u00fcnenthal, UCB, Zambon, Ca, AbbVie, TEVA, Lundbeck, and UCB Pharma, outside the submitted work. He has served on the editorial boards of Stem Cells and Stem Cells International.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}